| Domain | Best-supported LDS6-specific statement | Suggested ontology/identifier | Evidence scope/caveat |
|---|---|---|---|
| Disease identity | Loeys-Dietz syndrome type 6 is the *rarely used* designation for monoallelic **SMAD2**-related syndromic aortopathy within the broader Loeys-Dietz syndrome spectrum; some authors note the subtype label is inconsistently used. (pqac-00000004, pqac-00000006, pqac-00000000) | **SMAD2** (HGNC approved symbol); broader disease **MONDO:0018954** Loeys-Dietz syndrome; MeSH **D055947** | Direct for SMAD2 as LDS6; broader MONDO/MeSH refer to pan-LDS, not subtype-specific LDS6. |
| Core molecular cause | LDS6 is caused by heterozygous pathogenic variants in **SMAD2**, a receptor-regulated SMAD in canonical TGF-β signaling; Open Targets links SMAD2 to Loeys-Dietz syndrome with supportive genetic literature and monoallelic inheritance evidence. (pqac-00000002, pqac-00000004) | NCBI/Ensembl target: **SMAD2 / ENSG00000175387**; pathway **TGF-β signaling** | Direct association supported; variant-level LDS6 details remain sparse in retrieved sources. |
| Inheritance | Inheritance is **autosomal dominant / monoallelic**; across LDS, ~25% have an affected parent and many cases are de novo, with familial cases often milder. (pqac-00000002, pqac-00000006, pqac-00000010) | HPO inheritance term analogous to **Autosomal dominant inheritance**; MONDO broader LDS | Monoallelic inheritance supported for SMAD2/LDS association; de novo/familial proportions are from pan-LDS, not LDS6-only cohorts. |
| Hallmark vascular phenotype | The best-supported disease-defining manifestation for LDS6 is **thoracic aortic aneurysm/dissection predisposition** within a syndromic aortopathy phenotype. SMAD2 mutations were linked to a new LDS form after study of families with aneurysm/dissection and increased aortic-wall SMAD2 expression. (pqac-00000004) | HPO: **Aortic root dilatation**, **Thoracic aortic aneurysm**, **Aortic dissection**, **Arterial tortuosity** | Direct but limited foundational LDS6 evidence; frequencies/age-specific penetrance not available in retrieved subtype-specific data. |
| Extra-aortic syndromic features | LDS6 is expected to overlap with classic LDS features such as **hypertelorism**, **bifid uvula/cleft palate**, skeletal/connective-tissue findings, and mitral valve disease. (pqac-00000004, pqac-00000010) | HPO: **Hypertelorism**, **Bifid uvula**, **Cleft palate**, **Arachnodactyly**, **Joint hypermobility/stiffness**, **Mitral valve disease** | Mostly extrapolated from pan-LDS and TGFB3/TGFBR2 examples; LDS6-specific frequencies unavailable. |
| Pathway mechanism | SMAD2 acts downstream of TGFBR1/2; after receptor activation, phosphorylated SMAD2/3 complexes regulate transcription. LDS/related aortopathy literature supports paradoxical tissue-level **increased pSMAD2/3** despite impaired signaling in some cell contexts. (pqac-00000001, pqac-00000004, pqac-00000005, pqac-00000009) | GO: **TGF-beta receptor signaling pathway**, **SMAD protein signal transduction**, **regulation of transcription by RNA polymerase II** | Mostly pathway-level and non-LDS6-specific mechanistic inference; direct SMAD2-LDS6 functional assays were not retrieved. |
| Cellular context | Aortic disease mechanisms center on **vascular smooth muscle cells (VSMCs)** and likely endothelial/fibroblast contributions; lineage-specific LDS mouse work shows defective TGF-β/Smad induction in a susceptible VSMC lineage can localize root aneurysm. (pqac-00000005, pqac-00000011) | CL: **vascular smooth muscle cell**, **endothelial cell**, **fibroblast** | Strong for LDS pathway biology, but model used Tgfbr1-LDS rather than SMAD2-LDS6. |
| Anatomy affected | Primary site is the **aortic root/ascending thoracic aorta**; broader LDS may also involve aortic arch, descending aorta, branch vessels, and craniofacial/connective tissues. (pqac-00000005, pqac-00000007, pqac-00000010) | UBERON: **aortic root**, **ascending aorta**, **aortic arch**, **descending aorta**, **palate**, **arterial vasculature** | LDS6-specific anatomic distribution unresolved; broader LDS/HTAD imaging evidence used. |
| Diagnostics | Recommended workup is syndrome recognition plus **genetic testing** and **multimodality aortic imaging**. In HTAD/LDS, testing often uses multigene panels/WES, with cascade testing of first-degree relatives when positive; echo is first-line, CT/CMR define full aortic extent. (pqac-00000003, pqac-00000007, pqac-00000010) | Diagnostic resources: multigene **HTAD/LDS panel**, **WES**; imaging **TTE**, **CT/CCTA**, **CMR/MRA** | This is current practice extrapolated from pan-LDS/HTAD; no LDS6-specific diagnostic criteria were retrieved. |
| Differential diagnosis | Important differentials include **Marfan syndrome**, other **Loeys-Dietz subtypes**, **vascular Ehlers-Danlos syndrome**, and non-syndromic/familial HTAD. (pqac-00000003, pqac-00000006, pqac-00000012) | MONDO/HPO differential set; genes commonly contrasted: **FBN1, TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, COL3A1** | Extrapolated from broader inherited aortopathy literature. |
| Management | No randomized LDS-specific medical therapy trials were identified; current guidance is **blood-pressure control**, avoidance of stimulants/vasoconstrictors, exercise restriction, and multidisciplinary surveillance. Use of **ARBs (especially losartan)**, **beta-blockers**, or **ACE inhibitors** is commonly extrapolated from Marfan/LDS management. (pqac-00000007, pqac-00000008, pqac-00000010) | NCIT-style interventions: **Losartan**, **Angiotensin receptor blocker**, **Beta-adrenergic blocker**, **ACE inhibitor**, **Aortic surgery** | Pan-LDS/HTAD extrapolation; no LDS6-specific efficacy data retrieved. |
| Surgical intervention | Elective aortic surgery is used when anatomy or growth rate indicates high risk; retrieved LDS-oriented material notes intervention for critical aortic size/rapid growth, but subtype-specific diameter thresholds for LDS6 were not retrieved. (pqac-00000006, pqac-00000008) | NCIT: **Aortic root replacement**, **Vascular surgical procedure** | Threshold details here are not LDS6-specific and should not be overinterpreted. |
| Prevention/counseling | Secondary/tertiary prevention relies on **early diagnosis**, **cascade family screening**, serial imaging, and counseling on pregnancy/exertion risk. Prenatal diagnosis is possible when the familial pathogenic variant is known. (pqac-00000003, pqac-00000010) | Counseling concepts: **cascade screening**, **prenatal testing**, **genetic counseling** | Mostly pan-LDS evidence; LDS6-specific pregnancy outcome data not retrieved. |
| Epidemiology | LDS overall is rare; retrieved sources estimate prevalence as **below 1 in 100,000** or **1/25,000-1/100,000**. One recent review table estimated **LDS6/SMAD2 accounts for ~1-5% of LDS**. (pqac-00000006, pqac-00000009) | Broader disease epidemiology for **Loeys-Dietz syndrome** | Estimates are broad and not population-based for LDS6 specifically. |
| Models and translational resources | Relevant resources include **GenTAC** registry infrastructure for genetically triggered thoracic aortopathy and a completed **I-LoDiS** immunopathology study in LDS; patient-specific iPSC/endothelial disease-modeling work exists for LDS broadly. (pqac-00000012, pqac-00000009, pqac-00000006) | Clinical trials/registries: **NCT01322165** GenTAC; **NCT05472519** I-LoDiS | Valuable for LDS research, but not specific to SMAD2/LDS6 in the retrieved records. |
| Major evidence gaps | Major LDS6 gaps include: lack of subtype-specific prevalence, penetrance, phenotype frequencies, validated biomarkers, surgical thresholds, pregnancy outcomes, treatment response data, and retrieved direct SMAD2 functional variant studies. (pqac-00000000, pqac-00000002, pqac-00000006) | Evidence-gap annotation | Important to distinguish direct LDS6 evidence from broader LDS/HTAD extrapolation in any knowledge base entry. |


*Table: This table summarizes the best-supported findings for SMAD2-related Loeys-Dietz syndrome 6, while clearly separating subtype-specific evidence from broader Loeys-Dietz syndrome and hereditary thoracic aortic disease extrapolations. It is useful as a compact knowledge-base scaffold for curation and evidence-gap tracking.*